The FDA approved pirtobrutinib in October 2026 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have not yet been treated and do not have a specific ...

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The non-covalent ...

The FDA granted final approval to Alembic's generic venetoclax tablets, rated therapeutically equivalent to Venclexta, for CLL/SLL and newly diagnosed AML.

A retrospective single-center study of 75 treatment-naive CLL/SLL patients reports an 86.7% response rate with frontline ...

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL. Pirtobrutinib (Jaypirca) demonstrated a ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...